Skip to content

Based on the actual clinical research of real-world traditional Chinese medicine in the treatment of chronic liver failure

Based on the actual clinical research of real-world traditional Chinese medicine in the treatment of chronic liver failure

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100044187
Enrollment
Unknown
Registered
2021-03-12
Start date
2021-03-11
Completion date
Unknown
Last updated
2021-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic liver failure

Interventions

Sponsors

The First Affiliated Hospital of Guangxi University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Inpatients who meet the diagnostic criteria of chronic liver failure in the 2018 "Guidelines for the Diagnosis and Treatment of Liver Failure"; 2. Patients with previous liver cirrhosis; 3. Age between 18 and 65 years old, regardless of gender; 4. Those who voluntarily participated in this study and signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. Acute liver failure, subacute liver failure, chronic acute liver failure; 2. Chronic liver failure caused by other causes (including autoimmune, drug, toxicity and parasitic); 3. Pregnant or lactating women; 4. Patients with primary liver cancer; 5. Patients with other serious systemic diseases and mental illnesses; 6. Anti-HIV positive persons; 7. Those who have participated in other clinical trials within the past 3 months; 8. Those who are unwilling to cooperate; 9. At the time of enrollment, he had been combined with cerebral edema, severe infection (including septic shock, deep fungal infection, infection of more than two sites and double infection, etc.), type I hepatorenal syndrome (clinical features are severe, rapid, and progressive renal Failure, oliguria within a few days or 2 weeks, CRE > 221µmol/L), hepatopulmonary syndrome, hepatic encephalopathy above grade III, and gastrointestinal hemorrhage.

Design outcomes

Primary

MeasureTime frame
Case fatality rate;

Secondary

MeasureTime frame
Complication rate;Improvement rate;

Countries

China

Contacts

Public ContactMao Dewen

The First Affiliated Hospital of Guangxi University of Traditional Chinese Medicine

mdwboshi2005@163.com+86 13132905888

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026